ADAPTIVE BIOTECHNOLOGIES CORPORATION Impairment of Long-Lived Assets Held-for-use
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Impairment of Long-Lived Assets Held-for-use of $347.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-05-05
- ADAPTIVE BIOTECHNOLOGIES CORPORATION impairment of long-lived assets held-for-use for the quarter ending 2026-03-31 was $347.00K.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION impairment of long-lived assets held-for-use for the quarter ending 2025-12-31 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION impairment of long-lived assets held-for-use for the quarter ending 2025-03-31 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION impairment of long-lived assets held-for-use for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION impairment of long-lived assets held-for-use for fiscal 2024 was $7.21M, a 71.67% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION impairment of long-lived assets held-for-use for fiscal 2023 was $25.43M.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month | Impairment of Long-Lived Assets Held-for-use 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $347.00K 10-Q · filed 2026-05-05 | $347.00K derived: sum of 2 quarters · filed 2026-05-05 | $347.00K derived: sum of 3 quarters · filed 2026-05-05 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-05-05 | $0.00 derived: sum of 3 quarters · filed 2026-05-05 | $7.21M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $7.21M derived: sum of 3 quarters · filed 2026-02-26 | $7.21M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $7.21M derived: sum of 2 quarters · filed 2025-11-05 | $7.21M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $7.21M 10-Q · filed 2025-08-05 | $7.21M 10-Q · filed 2025-08-05 | |||
| 2023-12-31 | $25.43M 10-K · filed 2026-02-26 | $4.20M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |